Posted on October 7, 2019 by GlycoMark USA
New York, NY (October 7, 2019) — GlycoMark, Inc. announces additional study data describing GlycoMark® test results in patients on SGLT-2 inhibitors are being presented during the American Diabetes Association (ADA) Advancing Precision Diabetes Medicine Research Symposium on October 8 – 9, 2019 in Madrid, Spain. The GlycoMark test, an FDA-cleared and CE marked blood test used…
Read More
Posted on June 13, 2019 by GlycoMark USA
New York, NY (June 13, 2019)— GlycoMark, Inc. announced a new study “GlycoMark 1,5-Anhydroglucitol Values in Patients Taking SGLT-2 Inhibitors” presented at the American Diabetes Association (ADA) Scientific Sessions 2019 involving the GlycoMark test being used for patients with Type 2 diabetes that are being treated with an SGLT-2 inhibitor. SGLT-2 inhibitors are used to…
Read More
Posted on June 4, 2019 by GlycoMark USA
New York, NY (June 4, 2019) — GlycoMark, Inc. announces new data on the GlycoMark® test in patients on SGLT-2 inhibitors are being presented June 8 – 10 at the American Diabetes Association (ADA) Scientific Sessions 2019 in San Francisco. The GlycoMark test, an FDA-cleared and CE-marked blood test used to monitor glycemic control in patients…
Read More
Posted on November 18, 2018 by GlycoMark USA
New York, NY (November 19, 2018)– LabFinder.com, a convenient online platform for patients to schedule their laboratory and radiology tests and access test results, has announced the addition of the GlycoMark® test to its growing subscriber network. The GlycoMark test is an FDA-cleared blood test for detecting recent hyperglycemia and hyperglycemic excursions in patients with…
Read More
Posted on November 7, 2018 by GlycoMark USA
New York, NY (November 7, 2018)— GlycoMark, Inc. and PrismHealthDx, Inc. (PHDx) have announced an agreement to offer the GlycoMark® test to clinicians managing patients with diabetes. The GlycoMark test is the only FDA-cleared blood test for patients with diabetes that is specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring while fasting, postprandial, or…
Read More
Posted on July 6, 2018 by GlycoMark USA
Visit booth #748 at AADE18 organized by the American Association of Diabetes Educators in Baltimore, MD on August 17-20, 2018, to learn more about the GlycoMark test. This test is the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring in the fasting state, postprandial, or both). To schedule a meeting…
Read More
Posted on July 6, 2018 by GlycoMark USA
Are you attending the American Association of Clinical Chemistry (AACC) 70th Annual Scientific Meeting & Clinical Lab Expo in August? While in Chicago, meet with GlycoMark’s management team to learn more about the GlycoMark test – the only FDA-cleared blood test specific to detecting recent hyperglycemia and hyperglycemic excursions (occurring in the fasting state, postprandial,…
Read More
Posted on April 11, 2017 by GlycoMark USA
Agreement Facilitates Greater Accessibility for Patients and Clinicians to Important Diabetes Test New York, NY (April 11, 2017) – GlycoMark, Inc. announced today a partnership with Shiel Medical Laboratory to expanded distribution of the GlycoMark test throughout the Northeast U.S. GlycoMark is the only clinically available blood test that specifically indicates recent hyperglycemia in patients…
Read More
Posted on October 23, 2015 by GlycoMark USA
Upcoming webinar by the American Association for Clinical Chemistry (AACC) warns of variants and adducts that may affect accuracy of A1c tests New York, NY (October 23, 2015) – An upcoming webinar hosted by the AACC will discuss potential pitfalls of the hemoglobin A1c test due to conditional interferences that can affect the accuracy…
Read More
Posted on October 23, 2015 by GlycoMark USA
NEW YORK, NY (October 23, 2015) – In a new study published by the medical journal Diabetes involving more than 11,000 subjects, the GlycoMark test was used to help define links between hyperglycemic excursions and increased incidence of cardiovascular disease and death1. The recently published study involved analysis from the Atherosclerosis Risk In Communities (ARIC)…
Read More
The GlycoMark test is an FDA-cleared, non-fasting serum or plasma test for monitoring blood glucose variability in people with diabetes. The GlycoMark test provides quantitative measurement of 1,5-anhydroglucitol (1,5-AG) in serum or plasma. The test is for professional use, and is indicated for the intermediate term monitoring of glycemic control in people with diabetes.